secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apyx Medical Corp (APYX)
CIK:        0000719135
Form:       8-K
Filed at:   2024-01-22T23:59:59+00:00
Accession:  0000719135-24-000005
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apyx Medical publishes 483-patient study showing Renuvion safety after liposuction across multiple body areas
--------------------------------------------------------------------------------

- Analysis of 483 patients (1,184 body areas) found no new or increased risks vs. liposuction alone.
- Peer-reviewed publication in Aesthetic Surgery Journal Open Forum; data previously used for FDA 510(k) clearance in 2023.
- CEO states evidence strengthens clinical portfolio for Renuvion; no alternative FDA-cleared therapy exists for the indication.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/719135/000071913524000005/0000719135-24-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/719135/000071913524000005/apyx-20240122.htm
  HTML page:      https://secwatch.observer/filing/0000719135-24-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer